FDA rejects Ipsen rare-disease drug, more data and time needed to review
The FDA rejected Ipsen’s ultra-rare disease drug palovarotene, the company said, and has asked for more data from existing studies that will push another review …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
